Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
Market Cap | 109.203 Billion | Shares Outstanding | 2.18 Billion | Avg 30-day Volume | 13.865 Million |
P/E Ratio | 14.488 | Dividend Yield | 3.916 | EPS | 0.75 |
Price to Revenue | 2.6713 | Debt to Equity | 1.2939 | EBITDA | 18.442 Billion |
Price to Book Value | 4.1394 | Operating Margin | 16.9601 | Enterprise Value | 150.016 Billion |
Current Ratio | 1.178 | EPS Growth | 0.283 | Quick Ratio | 0.767 |
1 Yr BETA | 0.408 | 52-week High/Low | 78.62 / 48.25 | Profit Margin | 18.4778 |
Operating Cash Flow Growth | -6.5354 | Free Cash Flow to Firm (FCFF) TTM | 11.485 Billion | Free Cash Flow to Equity (FCFE) TTM | 6.637 Billion |
Altman Z-Score | 2.4498 | ||||
Earnings Report | 2024-02-02 |
Please sign in first
11.6 Thousand total shares from 2 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BOERNER CHRISTOPHER S. CHIEF EXECUTIVE OFFICER |
|
79,384 | 2023-11-28 | 3 |
LEUNG SANDRA EVP, GENERAL COUNSEL |
|
432,046 | 2023-11-21 | 2 |
|
35,500 | 2023-11-20 | 6 | |
CAFORIO GIOVANNI BOARD CHAIR AND CEO |
|
367,495 | 2023-10-10 | 3 |
GALLMAN CARI EVP, CORPORATE AFFAIRS |
|
206 | 2023-10-02 | 2 |
|
0 | 2023-09-30 | 5 | |
|
0 | 2023-09-30 | 5 | |
|
0 | 2023-09-30 | 5 | |
|
0 | 2023-09-30 | 5 | |
|
0 | 2023-09-30 | 5 | |
|
0 | 2023-09-30 | 5 | |
POWELL ANN EVP, CHIEF HUMAN RESOURCES |
|
27,868 | 2023-08-24 | 3 |
PLENGE ROBERT M EVP, CHIEF RESEARCH OFFICER |
|
6,784 | 2023-08-03 | 2 |
HIRAWAT SAMIT EVP,CHIEF MED.OFFR.,DRUG DEV. |
|
47,245 | 2023-07-01 | 2 |
WEESE MICHELLE EVP, CORPORATE AFFAIRS |
|
3,453 | 2023-07-01 | 2 |
LENKOWSKY ADAM EVP, CHIEF COMMERCIAL OFFICER |
|
10,574 | 2023-06-03 | 3 |
VESSEY RUPERT EVP & PRESIDENT, RESEARCH |
|
48,407 | 2023-05-03 | 2 |
GREENLEES SHARON SVP & CONTROLLER |
|
609 | 2023-05-02 | 2 |
MILY ELIZABETH EVP, STRATEGY & BD |
|
34,734 | 2023-04-01 | 2 |
SHANAHAN KARIN EVP, GLOB. PROD. DEV. & SUPPLY |
|
3,974 | 2023-04-01 | 2 |
ELKINS DAVID V EVP, CHIEF FINANCIAL OFFICER |
|
163,757 | 2023-03-10 | 1 |
MEYERS GREGORY SCOTT EVP, CHIEF DIGITAL & TECH OFF. |
|
3,497 | 2023-03-10 | 2 |
|
0 | 2023-02-01 | 1 | |
|
0 | 2023-02-01 | 1 | |
|
0 | 2023-02-01 | 2 | |
SANTIAGO KAREN MURPHY SVP & CONTROLLER |
|
16,704 | 2022-03-14 | 0 |
VON AUTENRIED PAUL EVP, CHIEF INFORMATION OFFICER |
|
63,536 | 2021-11-22 | 0 |
DUBOW ADAM SVP,CHIEFCOMPLIANCEÐICSOFF. |
|
14,749 | 2021-07-30 | 0 |
|
9,342 | 2021-06-30 | 0 | |
EID JOSEPH SVP,HEAD GLOB. MEDICAL AFFAIRS |
|
13,794 | 2021-06-03 | 0 |
SCHMUKLER LOUIS S EVP,PRES.,GLOB.PROD. & SUPPLY |
|
31,956 | 2021-05-10 | 0 |
|
26,648 | 2021-03-31 | 0 | |
|
26,999 | 2021-03-31 | 0 | |
|
40,501 | 2021-03-31 | 0 | |
|
0 | 2021-02-01 | 0 | |
AHMED NADIM EVP AND PRESIDENT, HEMATOLOGY |
|
40,855 | 2020-12-31 | 0 |
|
0 | 2020-06-30 | 0 | |
|
0 | 2020-06-30 | 0 | |
BANCROFT CHARLES A EVP, HEAD OF INTEGRATION |
|
529,844 | 2020-03-10 | 0 |
ELICKER JOHN E EVP, INVESTOR RELATIONS |
|
70,946 | 2020-03-10 | 0 |
METCALFE KATHRYN EVP, CORPORATE AFFAIRS |
|
0 | 2020-03-10 | 0 |
BIONDI PAUL SVP, HEAD OF STRATEGY & BD |
|
6,214 | 2019-10-02 | 0 |
LYNCH THOMAS J. JR. EVP & CHIEF SCIENTIFIC OFFICER |
|
22,223 | 2019-04-03 | 0 |
|
0 | 2018-09-30 | 5 | |
|
No longer subject to file | 2018-09-30 | 0 | |
GORDON MURDO EVP, CHIEF COMMERCIAL OFFICER |
|
No longer subject to file | 2018-08-01 | 0 |
CALDARELLA JOSEPH C SVP & CONTROLLER |
|
48,076 | 2017-09-06 | 0 |
NIELSEN ANNE CHIEF COMPLIANCE & ETHICS OFF |
|
37,974 | 2017-09-03 | 0 |
|
1,176,844 | 2017-04-06 | 0 | |
CUSS FRANCIS M EVP & CSO |
|
321,906 | 2017-03-10 | 0 |
BLIN EMMANUEL SVP, CHIEF STRATEGY OFFICER |
|
20,138 | 2017-03-10 | 0 |
|
0 | 2017-02-01 | 0 | |
|
0 | 2017-02-01 | 0 | |
|
2,110 | 2016-03-08 | 0 | |
|
79,851 | 2015-03-31 | 0 | |
MOED SAMUEL J SVP, STRAT PLAN & ANALYSIS |
|
31,615 | 2015-03-13 | 0 |
DANIELS BRIAN SVP GLOBAL DEV & MED AFFAIRS |
|
No longer subject to file | 2014-07-01 | 0 |
HELLER FRANCES K SVP, BUSINESS DEVELOPMENT |
|
4,218 | 2014-03-10 | 0 |
SIGAL ELLIOT EVP, CSO & PRESIDENT R&D |
|
195,300 | 2013-06-03 | 0 |
CAZALA BEATRICE J EVP COMMERCIAL OPERATIONS |
|
177,118 | 2013-05-31 | 0 |
|
0 | 2013-02-01 | 0 | |
|
0 | 2013-02-01 | 0 | |
CELENTANO JOHN E SVP HR PUBLIC AFFAIRS & PHILAN |
|
142,142 | 2012-03-06 | 0 |
LEVIN JEREMY M SVP STRAT TRANSACTIONS |
|
43,689 | 2011-10-01 | 0 |
CARLO DE NOTARISTEFANI PRES TECH OPS & SUPP FNCTNS |
|
8,432 | 2011-06-14 | 0 |
HOOPER ANTHONY C SVP COMOPS PRES USJAP INT |
|
208,419 | 2011-05-13 | 0 |
|
0 | 2011-02-01 | 0 | |
ZITO ROBERT T SVP & CHIEF COMM OFFICER |
|
35,469 | 2010-03-06 | 0 |
MCBRIDE ANTHONY A SVP HUMAN RESOURCES |
|
34,292 | 2010-03-06 | 0 |
HUET JEAN-MARC EVP & CFO |
|
25,000 | 2009-04-30 | 0 |
|
0 | 2007-12-31 | 0 | |
BONFIELD ANDREW R J EVP & CFO |
|
150,206 | 2007-10-01 | 0 |
BEAR STEPHEN E SVP, HUMAN RESOURCES |
|
76,257 | 2007-09-10 | 0 |
|
44,870 | 2006-09-29 | 0 | |
DOLAN PETER R FORMER CEO |
|
606,946 | 2006-09-08 | 0 |
BODNAR ANDREW G SVP, STRAT & MED & EXT AFFAIRS |
|
323,464 | 2006-09-08 | 0 |
|
2,500 | 2006-05-02 | 0 | |
|
2,500 | 2006-05-02 | 0 | |
|
22,932 | 2006-03-31 | 0 | |
|
42,402 | 2006-03-09 | 0 | |
MCGOLDRICK JOHN L EXECUTIVE VP |
|
223,999 | 2006-03-07 | 0 |
DIXON WENDY L CMO & PRES, GLOBAL MARKETING |
|
128,868 | 2006-03-07 | 0 |
HOWSON TAMAR D SVP, CORP & BUS DEVELOPMENT |
|
112,671 | 2006-03-07 | 0 |
WILLARD RICHARD K SVP & GENERAL COUNSEL |
|
203,300 | 2006-03-07 | 0 |
ZABOR DAVID L VP STRAT BUS INITIATIVES |
|
104,665 | 2006-03-07 | 0 |
DWYER EDWARD M VICE PRESIDENT & TREASURER |
|
41,257 | 2006-03-07 | 0 |
WOLGEMUTH RICHARD L SVP, GLOBAL REG SCIENCES |
|
68,936 | 2006-03-07 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-30 18:32:01 -0500 | 2023-11-28 | P | 3,071 | $48.86 | a | 79,384 | direct | |||||||||
LEUNG SANDRA - Officer EVP, GENERAL COUNSEL trust (slat) |
2023-11-24 14:38:18 -0500 | 2023-11-21 | J | 9,830 | $48.75 | a | 93,436 | indirect | -1.4871 | 0.6833 | 0.6833 | 6 | -2.09 | 4 | ||
2023-11-24 14:38:18 -0500 | 2023-11-21 | J | 9,830 | $48.75 | d | 331,414 | direct | -1.4871 | 0.6833 | 0.6833 | 6 | -2.09 | 4 | |||
2023-11-21 19:01:13 -0500 | 2023-11-20 | P | 8,500 | $49.81 | a | 35,500 | direct | 0.688 | -0.0809 | 0.688 | 2 | -1.4164 | 5 | |||
2023-11-03 18:30:28 -0400 | 2023-11-01 | A | 11,858 | a | 11,858 | direct | ||||||||||
2023-11-03 18:30:28 -0400 | 2023-11-01 | A | 17,788 | a | 17,788 | direct | ||||||||||
2023-10-12 19:13:05 -0400 | 2023-10-10 | G | 440 | d | 367,495 | direct | 1.2396 | -0.0177 | -13.1928 | 1.5938 | 3 | -14.1491 | 28 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-04 14:45:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-04 14:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-04 13:45:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-04 13:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-04 12:45:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 22:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 21:45:05 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 21:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 20:45:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 20:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 19:45:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 19:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 18:45:05 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 18:15:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 17:45:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 17:15:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 16:45:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 16:15:04 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 15:45:03 UTC | 5.07 | 0.25 | 0 |
BRISTOL-MYERS SQUIBB CO BMY | 2023-12-01 15:15:05 UTC | 5.07 | 0.25 | 0 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Master Neutral Fund | BMY | -13.0 shares, $-783.77 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Neutral 500 Fund | BMY | -42.0 shares, $-2651.46 | 2021-03-31 | N-PORT |
American Century Capital Portfolios, Inc.- AC Alternatives Market Neutral Value Fund | BMY | -5384.0 shares, $-318571.28 | 2021-09-30 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | BMY | -13266.0 shares, $-943079.94 | 2022-09-30 | N-PORT |
Waycross Independent Trust- WAYCROSS LONG/SHORT EQUITY FUND | BMY | -16300.0 shares, $-1004895.0 | 2023-08-31 | N-PORT |
Advantage Advisers Xanthus Fund, L.L.C.- Advantage Advisers Xanthus Fund, L.L.C. | BMY | -106284.0 shares, $-6168723.36 | 2023-09-30 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST II- AXS Market Neutral Fund | BMY | -1853.0 shares, $-107548.12 | 2023-09-30 | N-PORT |
Tidal Trust II- Blueprint Chesapeake Multi-Asset Trend ETF | BMY | -3623.0 shares, $-210278.92 | 2023-09-30 | N-PORT |
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
senator Thomas H Tuberville | republican | Senate | Filing | 2023-11-16 | 2023-10-17 | JT | P | $1,001-$15,000 | ||
Hon. Greg Stanton | House | Filing | 2023-10-26 | 2023-10-24 | SP | S | $1,001-$15,000 | |||
Hon. Greg Stanton | House | Filing | 2023-10-21 | 2023-09-26 | SP | P | $1,001-$15,000 | |||
senator Daniel S Sullivan | republican | Senate | Filing | 2023-09-22 | 2023-08-22 | JT | S | $1,001-$15,000 | ||
senator Daniel S Sullivan | republican | Senate | Filing | 2023-09-18 | 2023-08-22 | JT | S | $1,001-$15,000 | ||
Hon. Daniel Goldman | House | Filing | 2023-08-08 | 2023-07-12 | S | $15,001-$50,000 | ||||
senator Shelley M Capito | republican | Senate | Filing | 2023-06-14 | 2023-05-10 | SP | S | $1,001-$15,000 |